Two randomized controlled trials of SB742457 in mild-to-moderate Alzheimer's disease

Gareth Maheredwards,Carolyn Watson,John A Ascher, Carly Barnett,Diane Boswell,John T Davies,Manuel Castro Fernandez,Alexander Kurz,Orazio Zanetti,Beth Safirstein,Juan Paul Schronen,Marina Zvartauhind,Michael Gold

Alzheimer's & Dementia: Translational Research & Clinical Interventions（2015）

引用 43|浏览24

暂无评分

摘要

Neither study met the overall criteria for success, but as an adjunct to donepezil, SB742457 was associated with sustained improvements for up to 48 weeks in cognition and ADL, compared with donepezil alone.Clinical Trial Registration: Clinicaltrials.gov: Study 1 NCT00708552; Study 2 NCT00710684.

查看译文

关键词

5-HT6 antagonist,Alzheimer's disease,ADAS-Cog,CIBIC+,CDR-SB,Donepezil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要